Summary.-Previous studies suggested that aprotinin might enhance the host's immunological resistance to tumours. This possibility has now been further investigated by studying the behaviour of tumours in both hamsters and mice.
IT HAS previously been shown that the anti-proteinase, aprotinin, has considerable inhibitory properties against the growth and spread of tumour cells in animals (Latner, Longstaff and Turner, 1974) . Histological examination of the tumour from the aprotinin-treated animals indicated that tumour necrosis was accompanied by marked round-cell infiltration. This suggested to us that the proteolytic enzymes of malignant cells might be playing a part in relation to the inhibition of immunological attack by the host, and that the administration of aprotinin might prevent this process. It was decided, therefore, to test the effect of aprotinin on immunological resistance to tumour cell growth using a fibrosarcoma in hamsters and an adenocarcinoma in mice. In the latter case, cortisone was administered prior to tumour implantation and subsequent aprotinin treatment.
MATERIALS AND METHODS
Animals.-3-4-month-old inbred male Syrian hamsters and inbred female C3H mice (Heston specific) were used. The hamsters were raised in our laboratories and the mice were obtained commercially (Bantin and Kingman Limited, Aldbrough, North Humberside).
Tumour cells.-The cells used to raise tumours in the hamsters and the mice have been described previously (Latner et al., 1974 ). These will be subsequently referred to as TRES and SMA cells respectively. into the left dorso-lumbar region of each hamster. Eighteen days after implantation the animals were divided randomly into twro groups. One group was treated with 1 ml saline twice daily for 14 days, and the other with 1 ml aprotinin twice daily for the same length of time. After the treatment hald ended all animals were given another s.e. implant of 0-5 x 106 TRES cells; this time into the right scapula region. The times of first appearance of palpable tumours from the first and second grafts were noted.
Mouse observations.-Two groups of mice (Group A and Group B) were treated with either 0-1 ml saline or 0-1 ml cortisone acetate respectively for 28 days. After treatment, 0.5 ml SMA tumour (Latner et al., 1974) w%Aas implanted into the dorso-lumbar region of each mouse. The two groups were further subdivided into groups Al, A2
and BI, B2. Three days post-implantation, Group Al and Group Bi received 0 5 ml saline twice daily for 7 days, and Group A2 and Group B2 received 0 5 ml aprotinin twice daily for the same period. The mice were then left for one day, sacrificed, and each tumour dissected out to determine its wNet weight. RESULTS D)ifferences between groups were analysed statistically using the Mann Whitney U-test. The results obtained in the hamster groups are shown in the Figure. In the animals subsequently given saline and in those subsequently given aprotinin, the appearance of the first tumour graft was not significantly different (P > 0.5).
Hence, these two sets of data are pooled in the Figure, and referred to as " first graft ". After saline administration the second tumotur graft appeared significantly earlier then the first graft (P-0005). This did not happen with the aprotinin treated animals (P > 0.05), and the second tumour graft took significantly longer to develop in the aprotinin group than in those receiving saline The results obtained in the mouse groups are shown in the Table. Treatment of animals with aprotinin (A2) significantly inhibited tumour growth in animals pretreated with saline compared to the appropriate control group (Al) (P < 0 001). However, pretreatment of the animals with cortisone abolished the effectiveness of the aprotinin treatment (P > 0 05). Since there was no significant difference between groups Al, B1I and B2, a second experiment was performed using three groups, which corresponded to groups A2 (6 animals), Bi (8 animals) and B2 (8 animals). Here again there was no significant difference between tumour weights in groups B 1 and B2, but tumour weights in group A2 were once again significantly lower than in the other two (P < 0.01).
DISCUSSION
We believe that the results presented in this communication provide further evidence that aprotinin is enhancing the effectiveness of the immunological system in dealing with tumour cells. The reasons for this belief are two-fold. The first is that more rapid take of a second tumour graft in tumour-bearing animals can be interpreted as immune paralysis (Stjernsward, 1966) by the already present substantial growth. Thus abolition of this effect by aprotinin treatment suggests that the anti-proteinase is preventing such immune paralysis. Since the effect was observed only when the host had already been challenged with tumour cells, it would appear that the aprotinin was interfering directly with the immunological attack by the sensitized host rather than non-specifically stimulating the immunological system prior to receiving the tumour implant.
A second reason for the belief that the immunological response has been enhanced by aprotinin is concerned with the results obtained after cortisone treatment, which is known to brinig about immunosuppression. Although the mode of action of adrenal corticosteroids at the cellular level is poorly understood, recent in vitro studies have shown that corticosteroids suppress the effect of lymphotoxins (Williams and Granger, 1969) , monocyte chemotactic factor (Riihl et al., 1974) , macrophage aggregation factor (Gaumer et al., 1974) , and macrophage migration inhibitory factor (Balow and Rosenthal, 1973 We have previously suggested (Latner et al., 1974 ) that aprotinin may operate by inhibiting proteolytic digestion of tumour-specific antibodies attached to the T-lymphocyte. It could possibly be argued that aprotinin disappears from the circulation too rapidly (Vogel, Trautscheld and Werle, 1968) for this to occur.
It has now, however, been recognized that aprotinin binds specifically to sialosyl and uronosyl groups in carbohydratecontaining substances (Stoddart and Kiernan, 1973) . Consequently, injected aprotinin should bind to mucosubstances on the surfaces of sensitized lymphocytes and even tumour cells, and so maintain the level of the anti-proteinase in the immediate region of these cells. This would not affect the half-life of aprotinin as measured in plasma (Vogel et al., 1968) . The adherence of aprotinin to cell surfaces would account for the effect on the appearance of a second tumour graft even though the substance had ceased to be administered.
We are indebted to Bayer Pharmaceuticals Limited for their generous supply of aprotinin used throughout these investigations.
